Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$63.86
-1.2%		$59.56
$42.52
▼
$68.10
$132.06B0.2212.48 million shs7.53 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$45.91
-1.7%		$47.36
$35.12
▼
$64.16
$208.60B0.7612.85 million shs10.83 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.77
-0.1%		$25.12
$23.58
▼
$28.75
$152.75B0.3440.63 million shs23.16 million shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$17.64
+1.5%		$16.57
$12.99
▼
$18.90
$55.72B-0.084.06 million shs3.14 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-1.29%-1.19%+8.73%+11.96%+33.54%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-1.80%-2.74%-9.20%+2.69%-9.80%
Pfizer Inc. stock logo
PFE
Pfizer
-0.11%+0.27%+8.09%+5.79%+6.50%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
+1.37%+1.04%+7.29%+6.22%+19.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$63.86
-1.2%		$59.56
$42.52
▼
$68.10
$132.06B0.2212.48 million shs7.53 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$45.91
-1.7%		$47.36
$35.12
▼
$64.16
$208.60B0.7612.85 million shs10.83 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.77
-0.1%		$25.12
$23.58
▼
$28.75
$152.75B0.3440.63 million shs23.16 million shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$17.64
+1.5%		$16.57
$12.99
▼
$18.90
$55.72B-0.084.06 million shs3.14 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-1.29%-1.19%+8.73%+11.96%+33.54%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-1.80%-2.74%-9.20%+2.69%-9.80%
Pfizer Inc. stock logo
PFE
Pfizer
-0.11%+0.27%+8.09%+5.79%+6.50%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
+1.37%+1.04%+7.29%+6.22%+19.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.52
Moderate Buy$66.063.44% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.20
Hold$64.9441.44% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.285.62% Upside
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
2.25
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest TAK, NVO, PFE, and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$47.00
8/12/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
8/11/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/7/2026
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$35.00 ➝ $31.00
8/6/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform$47.00
8/5/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform ➝ Strong-Buy
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold ➝ Buy
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$75.00
(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.19B2.71$8.03 per share7.95$10.93 per share5.84
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.38$4.60 per share9.97$6.58 per share6.98
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.44$4.39 per share6.10$15.00 per share1.78
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$28.32B2.00$3.15 per share5.60$14.86 per share1.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$7.05B$4.5414.079.920.1718.87%66.90%14.74%10/29/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.0911.2313.624.2335.36%61.20%21.49%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7635.239.14N/A6.80%19.63%8.46%11/3/2026 (Estimated)
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
-$1.01B$0.3451.8911.76N/A3.80%10.95%5.34%10/29/2026 (Estimated)

Latest TAK, NVO, PFE, and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.77$0.96+$0.19$0.72$10.89 billion$11.98 billion
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.6820$0.77+$0.0880-$0.04$14.40 billion$15.03 billion
7/30/2026Q2 2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.60$2.04+$0.44$1.62$11.74 billion$12.97 billion
6/30/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$0.9440N/A$0.72N/A$11.98 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.523.95%+1.61%55.51%17 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.81%+21.74%42.79%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.42%-13.20%226.32%16 Years
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.482.72%-6.89%141.18%N/A

Latest TAK, NVO, PFE, and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/24/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.01%7/24/20267/24/20269/1/2026
8/5/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.57862.54%8/17/20268/17/20268/25/2026
6/17/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.634.34%7/2/20267/2/20268/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
1.89
1.53
1.38
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.27
0.96
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.58
1.14
0.62

Institutional Ownership

CompanyInstitutional Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
9.17%

Insider Ownership

CompanyInsider Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.05%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.04%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
32,5002.04 billion2.04 billionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
47,0003.20 billion3.20 billionOptionable

Recent News About These Companies

Takeda (NYSE:TAK) Climbs Into Focus On Sleep Disorder Milestone
August 14 at 6:54 PM  |  kalkinemedia.comK
Takeda Pharmaceutical (NYSE:TAK) Insider Elaine Mary Shannon Sells 3,978 Shares of Stock
August 13 at 7:37 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nyse-tak-insider-buying-and-selling-2026-08-13/
Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $239,502.60 in Stock
August 13 at 7:06 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-takeda-pharmaceutical-nysetak-insider-sells-23950260-in-stock-2026-08-13/
Elaine Mary Shannon Sells 3,978 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock
August 12 at 11:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/elaine-mary-shannon-sells-3978-shares-of-takeda-pharmaceutical-nysetak-stock-2026-08-12/
Takeda Pharmaceutical (NYSE:TAK) Insider Nicola Deidre Petal Greenway Sells 6,774 Shares of Stock
August 12 at 11:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/takeda-pharmaceutical-nysetak-insider-nicola-deidre-petal-greenway-sells-6774-shares-of-stock-2026-08-12/
Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $124,436.70 in Stock
August 12 at 11:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-takeda-pharmaceutical-nysetak-insider-sells-12443670-in-stock-2026-08-12/
Takeda Pharmaceutical (NYSE:TAK) Insider Sells $392,564.70 in Stock
August 12 at 11:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/takeda-pharmaceutical-nysetak-insider-sells-39256470-in-stock-2026-08-12/
Gabriele Ricci Sells 25,088 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock
August 12 at 11:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/gabriele-ricci-sells-25088-shares-of-takeda-pharmaceutical-nysetak-stock-2026-08-12/
Takeda Pharmaceutical (NYSE:TAK) General Counsel Natalie Anne Marie Furney Sells 30,868 Shares of Stock
August 12 at 11:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/takeda-pharmaceutical-nysetak-general-counsel-natalie-anne-marie-furney-sells-30868-shares-of-stock-2026-08-12/
Takeda Pharmaceutical (NYSE:TAK) Insider Sells $531,519.30 in Stock
August 12 at 11:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/takeda-pharmaceutical-nysetak-insider-sells-53151930-in-stock-2026-08-12/
Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells 47,586 Shares
August 12 at 11:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-takeda-pharmaceutical-nysetak-insider-sells-47586-shares-2026-08-12/
Takeda Pharmaceutical (NYSE:TAK) CEO Sells $1,523,439.00 in Stock
August 12 at 11:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/takeda-pharmaceutical-nysetak-ceo-sells-152343900-in-stock-2026-08-12/
Takeda Pharmaceutical (NYSE:TAK) Insider Andrew Stewart Plump Sells 165,393 Shares of Stock
August 12 at 11:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/takeda-pharmaceutical-nysetak-insider-andrew-stewart-plump-sells-165393-shares-of-stock-2026-08-12/
Silence Therapeutics aims at Takeda with new data in rare blood cancer
August 10, 2026  |  statnews.comS
Royal Bank of Canada Grows Position in Takeda Pharmaceutical Co. $TAK
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-royal-bank-of-canada-grows-position-in-takeda-pharmaceutical-co-tak-2026-08-09/
Takeda’s Brazil IBD Study Wraps Up, Offering Fresh Clues on Vedolizumab Performance
August 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/takedas-brazil-ibd-study-wraps-up-offering-fresh-clues-on-vedolizumab-performance?utm_source=marketbeat.com&utm_medium=referral
Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932968-takedas-pipeline-looks-encouraging-but-generic-erosion-is-a-near-term-concern
Takeda Pharmaceutical (NYSE:TAK) Raised to Hold at Zacks Research
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/takeda-pharmaceutical-nysetak-raised-to-hold-at-zacks-research-2026-08-06/
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
August 5, 2026  |  aol.comA
U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
August 5, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260805760759/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ORZEYFUL%E2%84%A2-oveporexton-the-First-and-Only-Medicine-to-Treat-the-Underlying-Cause-of-Narcolepsy-Type-1/
US FDA approves Takeda's sleep disorder pill
August 5, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-takedas-sleep-disorder-pill-2026-08-05/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie logo on a curved wall in an office lobby, with a laboratory and vials visible nearby.
AbbVie Quietly Solved Its Biggest Problem—Now What?
By Thomas Hughes | August 2, 2026
Illustration of a chip-like structure displaying AMD and Anthropic logos connected by colorful data streams in a server room.
AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle
By Jeffrey Neal Johnson | July 23, 2026
Smartphone displaying the Uber logo stands on a marble ledge with keys, overlooking a city skyline.
Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
By Jeffrey Neal Johnson | July 16, 2026
PayPal logo displayed on a curved reception desk in a modern office lobby with city skyline views.
PayPal Stock Surges on $53 Billion Stripe-Advent Buyout Bid
By Jeffrey Neal Johnson | July 16, 2026
An upward-trending arrow drawn in beach sand, symbolizing rising stock prices, with beachgoers in the background.
3 Stocks Taking Very Different Routes Through the Summer Rally
By Nathan Reiff | August 5, 2026
Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$63.86 -0.79 (-1.22%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$63.99 +0.13 (+0.21%)
As of 08/14/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$45.91 -0.81 (-1.73%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$45.89 -0.02 (-0.04%)
As of 08/14/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer stock logo

Pfizer NYSE:PFE

$26.77 -0.03 (-0.10%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$26.78 +0.00 (+0.00%)
As of 08/14/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Takeda Pharmaceutical stock logo

Takeda Pharmaceutical NYSE:TAK

$17.64 +0.25 (+1.46%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$17.76 +0.12 (+0.69%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas